Compare · ELVN vs NVO
ELVN vs NVO
Side-by-side comparison of Enliven Therapeutics Inc. (ELVN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELVN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 48.2x ELVN ($4.47B).
- Over the past year, ELVN is up 202.4% and NVO is down 14.8% - ELVN leads by 217.2 points.
- Both names hit the wire about 9 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 11 for ELVN).
- Company
- Enliven Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $61.38+0.55%
- $47.15-3.08%
- Market cap
- $4.47B
- $215.46B
- 1M return
- +14.31%
- -7.46%
- 1Y return
- +202.39%
- -14.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 9
- 9
- Recent ratings
- 11
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ELVN
- CHIEF FINANCIAL OFFICER Hohl Benjamin sold $352,551 worth of shares (6,018 units at $58.58) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 40,036 units (SEC Form 4)
- CHIEF MEDICAL OFFICER Collins Helen Louise exercised 5,000 shares at a strike of $2.48 and sold $292,931 worth of shares (5,000 units at $58.59) as part of a pre-agreed trading plan (SEC Form 4)
- William Blair initiated coverage on Enliven Therapeutics
- Barclays initiated coverage on Enliven Therapeutics with a new price target
- Director Derynck Mika K exercised 158,795 shares at a strike of $10.84 and sold $9,561,587 worth of shares (158,795 units at $60.21) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Enliven Therapeutics Inc.
- SEC Form 10-Q filed by Enliven Therapeutics Inc.
- Enliven Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
- CHIEF FINANCIAL OFFICER Hohl Benjamin sold $316,780 worth of shares (6,018 units at $52.64) as part of a pre-agreed trading plan and exercised 1,072 shares at a strike of $2.48, decreasing direct ownership by 10% to 46,054 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S